Overview
Microcephalus cardiomyopathy syndrome is a fatal infantile condition characterized by cardiomyopathy and neurological impairment, associated with cytochrome c oxidase (COX) deficiency due to mutations in the SCO2 gene, which is crucial for COX assembly. 1Diagnosis
Clinical Presentation: Fatal cardioencephalomyopathy in infants.
Genetic Testing: Identification of mutations in SCO2 gene.
Biochemical Analysis: Demonstration of COX deficiency, particularly severe in cardiac and skeletal muscle.
Immunohistochemistry: Loss of mtDNA-encoded COX subunits in affected tissues. 1Management
Supportive Care: Focus on symptom management and supportive measures due to lack of specific curative treatments.
Multidisciplinary Approach: Involvement of cardiology, neurology, and genetics specialists.
Genetic Counseling: Essential for families with identified SCO2 mutations. 1Special Populations
Pediatrics: Condition exclusively affects infants, with no specific management variations noted for other pediatric age groups. 1Key Recommendations
Genetic Testing for SCO2 Mutations: Essential for diagnosis in infants presenting with fatal cardioencephalomyopathy and suspected COX deficiency. (Evidence: Expert opinion) 1
Multidisciplinary Care Team: Recommended to manage complex clinical manifestations involving cardiac and neurological systems. (Evidence: Expert opinion) 1
Supportive Care Focus: Given the fatal nature and lack of curative treatments, prioritize supportive care strategies tailored to individual patient needs. (Evidence: Expert opinion) 1References
1 Papadopoulou LC, Sue CM, Davidson MM, Tanji K, Nishino I, Sadlock JE et al.. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nature genetics 1999. link